Program
lumateperone
Also written as “Lumateperone”, “ITI-007” and “Lumateperone high dose”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Autism Spectrum Disorder · Alzheimer Disease, led by Johnson & Johnson.
Drug pageLumateperone: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 256 open or running | phase 3since Oct 31, 2014 | Dec 16, 2011 | Apr 5, 2027phase 3 · NCT05850689 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 8 earlier studies, Dec 16, 2011 to Jun 27, 2016.
- Dec 9, 2015Named lumateperoneINNProposed as its International Nonproprietary Name in WHO's List 114 · before, ITI-007
- Aug 11, 2017Phase 3 study in Bipolar DisorderNCT03249376 · 381 enrolled · United States, Bulgaria, Colombia and more
- Feb 24, 2020Phase 3 study in Bipolar DisorderNCT04285515 · 488 enrolled · United States, Bulgaria, Russian Federation and more
- Feb 26, 2021Phase 1 study in SchizophreniaNCT04779177 · 26 enrolled · United States
- Jun 30, 2021Phase 3 study in SchizophreniaNCT04959032 · 592 enrolled · United States, Bulgaria, Poland and more
- Jul 22, 2021Phase 3 study in Depressive Disorder, MajorNCT04985942 · 485 enrolled · United States, Bulgaria, Czechia and more
- Sep 20, 20212 phase 3 studies in Depressive Disorder, MajorNCT05061719, NCT05061706
- Apr 28, 2023Phase 3 study in Depressive Disorder, MajorNCT05850689 · 470 planned · United States, Bulgaria, France and more
- Jan 19, 2024Phase 3 study in SchizophreniaNCT06229210 · 300 planned · United States, Colombia, Serbia
- Apr 15, 2024Phase 3 study in Bipolar DisorderNCT06372964 · 384 planned · United States, Colombia, India and more
- Jun 12, 20242 phase 3 studies in Bipolar DisorderNCT06462612, NCT06462586
- Aug 14, 2024Phase 1 study in Autism Spectrum DisorderNCT06557902 · 33 enrolled · United States
- Oct 2, 2024Phase 1 study in SchizophreniaNCT06627413 · 52 enrolled · United States
- Nov 13, 20242 phase 3 studies in Irritability Associated With Autism Spectrum DisorderNCT06690398, NCT06706674
- Jul 30, 2026Phase 3 study in Depressive Disorder, MajorNCT07747389 · 585 planned
Ahead
- Apr 5, 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT05850689
- Jun 21, 2027Primary completion: phase 3 study in Irritability Associated With Autism Spectrum DisorderNCT06706674
- Jun 21, 2027Primary completion: phase 3 study in Irritability Associated With Autism Spectrum DisorderNCT06690398
- Sep 20, 2029Primary completion: phase 3 study in Depressive Disorder, MajorNCT07747389
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor”ChEMBL 37, by rule
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07747389Depressive Disorder, Major | 3 | Not yet recruiting | Sep 20, 2029 | 585 |
| NCT06706674Irritability Associated With Autism Spectrum Disorder · United States | 3 | Recruiting | Jun 21, 2027 | 160 |
| NCT06690398Irritability Associated With Autism Spectrum Disorder · United States, Serbia | 3 | Recruiting | Jun 21, 2027 | 160 |
| NCT06627413Schizophrenia · United States | 1 | Completed | Nov 20, 2025 | 52 |
| NCT06557902Autism Spectrum Disorder · United States | 1 | Completed | Nov 26, 2025 | 33 |
| NCT06462612Bipolar Disorder · United States, Bulgaria, Romania and more | 3 | Completed | May 15, 2026 | 351 |
| NCT06462586Bipolar Disorder · United States, Bulgaria, Croatia and more | 3 | Completed | Feb 24, 2026 | 354 |
| NCT06372964Bipolar Disorder · United States, Colombia, India and more | 3 | Recruiting | Oct 31, 2031 | 384 |
| NCT06229210Schizophrenia · United States, Colombia, Serbia | 3 | Recruiting | Apr 28, 2032 | 300 |
| NCT05850689Depressive Disorder, Major · United States, Bulgaria, France and more | 3 | Recruiting | Apr 5, 2027 | 470 |
| NCT05061719Depressive Disorder, Major · United States, Bulgaria, Czechia and more | 3 | Completed | Oct 14, 2024 | 812 |
| NCT05061706Depressive Disorder, Major · United States, Argentina, Bulgaria and more | 3 | Completed | Apr 12, 2024 | 480 |
| NCT04985942Depressive Disorder, Major · United States, Bulgaria, Czechia and more | 3 | Completed | Feb 22, 2024 | 485 |
| NCT04959032Schizophrenia · United States, Bulgaria, Poland and more | 3 | Completed | Jul 25, 2024 | 592 |
| NCT04779177Schizophrenia · United States | 1 | Completed | Jul 30, 2022 | 26 |
| NCT04285515Bipolar Disorder · United States, Bulgaria, Russian Federation and more | 3 | Completed | Nov 30, 2022 | 488 |
| NCT03249376Bipolar Disorder · United States, Bulgaria, Colombia and more | 3 | Completed | Mar 1, 2019 | 381 |
| NCT02817906Aberrant Motor Behavior in Dementia · United States | 3 | Terminated | Jan 30, 2019 | 177 |
| NCT02600507Bipolar Disorder · United States, Bulgaria, Russian Federation and more | 3 | Completed | Jul 2, 2020 | 529 |
| NCT02600494Bipolar Disorder · United States | 3 | Completed | Jan 28, 2019 | 554 |
| NCT02469155Schizophrenia · United States | 3 | Completed | Aug 2016 | 696 |
| NCT02288845Schizophrenia · United States | 2 | Completed | Jul 2015 | 14 |
| NCT02282761Schizophrenia · United States | 3 | Completed | Jul 2015 | 450 |
| NCT02078310Alzheimer Disease · United States | 2 | Completed | Aug 2014 | 35 |
| NCT01499563Schizophrenia · United States | 2 | Completed | Aug 2013 | 335 |
How it is read
Names in the registry
- “Lumateperone”, 11 entries
- “ITI-007”, 7 entries
- “Lumateperone high dose”, 2 entries
- “Lumateperone low dose”, 2 entries
- “Lumateperone 42 mg”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 8 studies
- Bipolar Disorder, 7 studies
- Depressive Disorder, Major, 5 studies
- Autism Spectrum Disorder, 3 studies
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.